NCT00675649View on ClinicalTrials.gov

A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2008

Conditions
Asthma
Interventions
BIOLOGICAL

CNTO 148 / Golimumab

100 mg sc injection every 4 weeks from week 0 to week 20

BIOLOGICAL

placebo

placebo sc injection every 4 weeks from week 0 to week 20

Sponsors

Lead Sponsor

Centocor, Inc.
All Listed Sponsors
lead

Centocor, Inc.

INDUSTRY